What is Mucosolvan?

The drug Mucosolvan contains Ambroxol hydrochloride 30mg, which is made in the form of tablets. The drug is indicated for the treatment of sputum-thinning conditions of acute and chronic bronchopulmonary diseases, associated with abnormal mucus secretion, or possibly due to impaired mucus transport. However, the drug Mucosolvan can cause some unwanted side effects such as: Angioedema, rash, urticaria, ... Therefore, before using Mucosolvan, patients should learn carefully and should consult consult a physician.

What is Mucosolvan? Mucosolvan contains ambroxol hydrochloride which has been shown to increase respiratory secretions. This compound increases the production of surfactants in the lungs and stimulates the activity of villi.
This process improves the flow and transport of mucus, which has the effect of purifying the mucus of the villi. Improvements in villi mucin clearance have been observed in clinical studies. The increased secretion and mucin-clearing effects of the villi help create favorable conditions for expectoration and relief of cough.
Furthermore, the compound in Mucosolvan has a local anesthetic effect and has also been observed in rabbit eye models. This process can be explained by the sodium channel blocking properties. This suggests that in vitro, the ambroxol component in the neurosodium channel blocker Mucosolvan is cloned and this binding can be restored, but is also concentration dependent.

In vitro, ambroxol compounds also significantly reduced the release of cytokines from blood and tissue-associated mononuclear or multinucleated cells.
In a clinical study in patients with sore throat, Mucosolvan was shown to significantly reduce pain and redness in the throat.
The pharmacological properties of Mucosolvan may be related to observations in clinical studies regarding the efficacy of the compound ambroxol in the treatment of upper respiratory tract symptoms. At the same time, the results show that the drug helps to quickly relieve pain as well as discomfort related to other painful areas such as ears, nose, and trachea.
When taking Mucosolvan into the body, the ambroxol component is quickly absorbed and diffused into the blood, from there to the tissues with the highest drug concentration in the lungs. Bioavailability of the drug accounts for about 70% and maximum plasma concentrations are reached between 0.5 and 3 hours after dosing.
At therapeutic doses, the drug can bind to plasma proteins approximately 90%, and the plasma half-life ranges from 7 to 12 hours. Mucosolvan is metabolised in the liver and eliminated by the kidneys about 83%.

Mucosolvan 30mg is indicated for use in the treatment of sputum thinning for acute and chronic bronchopulmonary diseases. At the same time, these diseases are also associated with abnormal mucus secretion or impaired mucus transport
However, this drug is also contraindicated in some cases such as patients with a history of hypersensitivity to the ingredients of the drug, especially ambroxol hydrochloride or other excipients of the drug, or people with rare genetic diseases may be incompatible with the excipients in the drug.

Mucosolvan is available in tablet form and is taken orally. The drug can be used with or without food or before / after meals and should be taken with water with the therapeutic dose for adults 1 tablet / time and used 3 times a day. The therapeutic effect can be increased by changing the way of using the drug with a dose of 2 tablets and taken twice a day.
Mucosolvan can be used by adults and children over 12 years old.
For children from 6 to 12 years old, use half a tablet, 2 to 3 times a day.
Mucosolvan tablets are not indicated for use in children under 6 years of age.
Where treatment is indicated for acute respiratory disease, a thorough examination should be performed if symptoms do not improve or may even worsen with treatment.
The dosage of Mucosolvan above is for reference only. Therefore, if you use the drug to improve your health, you need to learn carefully and consult a doctor.
If you forget to take your medicine, use the missed dose as soon as you remember. However, if the missed dose of Mucosolvan is close to your next dose, skip the missed dose and take the next dose. You should note that you should not use a double dose of Mucosolvan, because this can cause bad symptoms that affect health.
In case of drug overdose, it is necessary to stop using Mucosolvan and see a doctor for timely support.

Mucosolvan may cause some unwanted side effects for users such as immune system disorders, anaphylactoid reactions including anaphylaxis, angioedema, rash, urticaria, itching or other reactions. other sensitivities. Or digestive system disturbances, nausea and vomiting, diarrhea, dyspepsia, abdominal pain may occur.
If during the course of treatment, there are abnormal signs, the patient should stop using the drug and notify the doctor for a timely treatment plan.

Some notes when using Mucosolvan:
Although there are very few reports of severe skin lesions such as Stevens-Johnson syndrome or toxic epidermal necrolysis associated with the use of expectorants. However, these effects may be explained by the severity of the underlying medical condition or by the drugs used. Furthermore, in the early stages of Stevens-Johnson syndrome, the patient may first present with nonspecific manifestations along with fever, body aches, rhinitis, cough, or possibly a sore throat. These nonspecific manifestations can lead to improper treatment of symptoms with cough and cold medicines.
If new lesions or mucous membranes appear, caution should be exercised when using the drug because it contains ambroxol hydrochloride. Tablets containing 171mg lactose equivalent to 684mg lactose for the maximum daily therapeutic dose should not be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Use Mucosolvan. For pregnant women when using Mucosolvan, the ambroxol hydrochloride component will cross the placental barrier. Clinical studies, though, have not shown direct or indirect harmful effects of the drug on pregnancy or fetal development, childbirth or the development of the child at birth. In clinical experience after 28 weeks of pregnancy there is no evidence of harmful effects on the fetus. However, when using Mucosolvan for this subject, caution should also be exercised. Especially in the first 3 months of pregnancy, the use of Mucosolvan is not recommended.
For women who are breast-feeding, ambroxol hydrochloride can be secreted into breast milk, so Mucosolvan is not recommended for use in nursing women even though there are no adverse effects. affect children. Subclinical studies of the drug's effects have shown no direct or indirect harmful effects on fertility. However, before using the drug, it is necessary to carefully research and consult a doctor.